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PODIUM SESSION IV: RISK ASSESSMENT STUDIES
RA1
CAN THE PUBLIC’S RISK PREFERENCE WHEN WEIGHING A DRUG’S
RISK/BENEFIT BE TRUSTED?
Wilson L, Pelletier D, Motter C, Basu R, Owen M, Kuan RK, Cheng Y
University of California, San Francisco, San Francisco, CA, USA
OBJECTIVES: To measure utility (risk preference) of individuals deciding to take a 
multiple sclerosis (MS) drug given varying risks/beneﬁ ts. METHODS: A computerized 
measure based on ProSPEQT software was developed to measure Standard Gamble
utility. 45 healthy individuals were presented with 9 health states varying MS disease 
severity (mild, moderate, severe) and asked their preferences to remain in that state 
or gamble on taking a drug with varying probabilities of 3 levels of MS improvements
(mild, average, substantial) but also corresponding probabilities of death. Student’s
t-test analyzed affects of gender, age-groups, education, and MS experience on utility. 
RESULTS: Subjects ranged from 16–69 years (mean  40 years) and 44.4% knew
someone with MS. In general, healthy individuals were willing to accept substantial 
risk of death for even mild MS improvements and accepted more risk for severe MS 
and greater disease improvements. The lowest mean score was for mild MS improve-
ment given mild MS (0.082; 95% CI [0.045–0.120]). The highest score was for sub-
stantial MS improvement given severe MS (0.382; 95% CI [0.295–0.469]). Only
education signiﬁ cantly affected utility for mild improvement in mild MS (p  0.03). 
Individuals with bachelor’s degree or less had 7.7% higher score than post-graduates.
CONCLUSIONS: We found it surprising how much risk of death healthy individuals
were willing to accept (8–38%). This is much greater than the 1/1000 actual risk for 
natalizumab in MS treatment, which the FDA removed from the market. MS patients’
voiced preferences helped get that drug back on the market, showing importance
of shared health decision-making. The FDA and physicians might ﬁ nd it difﬁ cult 
to approve or prescribe drugs with 38% risk of death. However, these preferences
indicate healthy individuals may be less risk-averse than the FDA or physicians,
emphasizing the importance of including the public when weighing risks and beneﬁ ts
of drugs.
RA2
RISK OF DIABETES ASSOCIATED WITH THE USE OF ATYPICAL
ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS – A TEXAS
MEDICAID STUDY
Nagar SP, Mehta S, Zweifel P, Chen H
University of Houston, Houston, TX, USA
OBJECTIVES: To examine the risk of developing diabetes among children and ado-
lescents who received atypical antipsychotic drug. METHODS: This study is a retro-
spective cohort analysis using 2003–2004 Texas Medicaid claims data. Patients were 
included in the cohort if they met the following criteria: 6 to 18 years of age, new
users of atypical antipsychotics and had not received a diagnosis of diabetes (ICD-9-
CM code: 250.xx) or a prescription claim of an anti-diabetic drug both before and 
one month after the initiation of an antipsychotic treatment. Risk of newly developed
diabetes following antipsychotic treatment was observed during a 12 month follow-up 
period. Kaplan-Meier survival curves and Cox proportional-hazards regression model
were employed to examine the time dependent risk (hazard) of diabetes and hazards 
ratio were obtained. Age, gender, race and exposure to other diabetogenic medications 
were controlled in the analysis. RESULTS: A total of 4096 patients were identiﬁ ed as
new atypical antipsychotic users. The average age of the cohort was 11 years, most
of the patients were male (65%), and Hispanics (36.5%). Cox-proportional hazard 
model analysis revealed no signiﬁ cant association between use of atypical antipsy-
chotic use and risk of diabetes (Hazards Ratio, HR  1.11, 95% CI  0.81–1.53). 
Children in the older age group of 15–18 years, females and Hispanics had higher risk 
of developing diabetes. Concurrent treatments with corticosteroids, beta-blockers,
thiazides and antidepressants were also associated with increased incidence of diabe-
tes. CONCLUSIONS: Our results indicate that there is no increase in the risk of 
developing diabetes in pediatric patients receiving atypical antipsychotics. The discrep-
ancy in the ﬁ ndings between adults and children implies that psychotropic medications
might function differently in pediatric population from adults. It is necessary to com-
prehensively assess the risks associated with common off-label medications, such as 
atypical antipsychotics, in children and adolescents.
RA3
A BAYESIAN DECISION–ANALYTIC ECONOMIC MODEL TO OPTIMIZE
ALLOCATION OF RISK IN PAY–FOR–PERFORMANCE PAYMENT
ARRANGEMENTS
Mallick R1, Hollenbeak C2
1Risk Sharing Solutions, Collegeville, PA, USA, 2Penn State College of Medicine, Hershey, 
PA, USA
OBJECTIVES: Performance-based payment arrangements for innovative drugs seek
to allocate ﬁ nancial risk of interventions between manufacturers and payers. Given
operational challenges in monitoring real-world outcomes, effective risk sharing
mechanisms may require prediction of incremental survival/quality-adjusted life years
(QALYs) conditional on surrogate markers, for example, complete remission (CR) or 
partial remission (PR). In accepting a risk-sharing arrangement that reimburses only
for remitters, payers should minimize the “false-positive” (FP) risk: early remitters 
who subsequently have limited QALYs. Manufacturers should minimize the “false-
negative” (FN) risk: early non-remitters who subsequently have prolonged QALYs. 
A Bayesian decision framework can be used to choose among multiple likelihood 
(predictive) priors to optimize the posterior economic risk trade-off for payers and 
manufacturers. METHODS: A Bayesian decision-analytic, hypothetical data-based, 
cost-effectiveness model was developed. Prior probabilities and QALYs were assigned 
for 6-, 3-, and 1-month survival, as were treatment costs. A plausible prior likelihood 
(predictive) structure represented the (ROC) relationship between the sensitivity and 
speciﬁ city of CR/PR in predicting survival. Expected (posterior) probabilities of sur-
vival, conditional on CR/PR, were generated. At a threshold of $50,000/QALY, the 
cost-effectiveness of the intervention, conditional on achieving CR/PR, and an optimal 
sensitivity-speciﬁ city trade-off was derived. RESULTS: At a hypothetical treatment 
cost of $5,000/month for a 4-month cycle, a minimal FP of 13% (maximum speciﬁ city
of 87%) and a minimal FN of 33% (maximum sensitivity of 67%) emerged as neces-
sary to be accepted by payers and manufacturers respectively to ensure viable risk-
sharing. At higher sensitivity, payer risk did not meet the reimbursement threshold, 
while at higher speciﬁ city, manufacturers would assume excessive ﬁ nancial risk. Other
illustrations will be discussed. CONCLUSIONS: Manufacturers should propose evi-
dence-based payment arrangements that utilize clinical trial data to develop economic
implications of being at various points on the ROC curve in order to optimize the
trade-offs between payer and manufacturer incentives.
RA4
METABOLIC SYNDROME RISK FACTORS FOR NATIVE BORN AND FIRST
GENERATION ADOLESCENTS (12–17) IN THE UNITED STATES
Hufstader MA1, Sias S1, Vaidya V2, White-Means S1
1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee, 
Memphis, TN, USA
OBJECTIVES: To contrast the factors that are associated with metabolic syndrome
risk for both adolescents overall and Hispanic adolescents in the U.S. METHODS: At 
risk is deﬁ ned as having three or more of the following: elevated fasting glucose, ele-
vated SBP, elevated DBP, elevated triglycerides, elevated BMI, elevated waist circumfer-
ence, or low HDL. Logistic regression and NHANES 2003–2006 data were used to 
examine the impact on metabolic syndrome risks; gender, race, ethnicity, immigrant 
status, income, insurance, parental education, activity levels, number of school lunches
and breakfasts per week, milk consumption, language preference, and number of 
meals outside the home per week. Adolescents in the United States overall are com-
pared with Hispanic adolescents in the U.S. A signiﬁ cance level of 0.05 was used. 
Weighted sample sizes for Hispanic adolescents and adolescents in the U.S. are 
8,178,714, and 50,837,204. RESULTS: Major differences include the decreased risk
(42%) for adolescent females overall in the U. S., and the increased risk (17%) for
Hispanic females in the U.S. Notably, for those Hispanics that are ﬁ rst generation, 
their risk is increased by 65%. For adolescents overall in the U.S., low or middle
income levels increase risk three times, while low and middle income level Hispanic
adolescents in the U.S. have a risk decrease of 77% and 69% respectively. For every
meal eaten outside the home per week (excluding school meals) the risk increases for 
adolescents in the U.S. by 4% and by 13% for Hispanic adolescents in the U.S.
CONCLUSIONS: These adolescents are at risk for acute cardiovascular endpoints, 
higher medical utilization and expenditure, and lower quality of life. Interventions
should focus on education regarding healthy eating outside the home with limited 
resources. This analysis is the high price of acculturation for Hispanic ﬁ rst generation 
adolescents.
PODIUM SESSION IV: RESPIRATORY–RELATED DISORDERS – 
Outcomes Research & Health Care Policy Studies
RR1
QUARTERLY ASSESSMENT OF SHORT ACTING b–AGONIST USE 
AS A PREDICTOR OF SUBSEQUENT HEALTH CARE SERVICES USE
FOR ASTHMATICS IN THE U.S.
Blanchette CM1, Silver H1, Petersen H1, Kamble S2, Meddis D3, Gutierrez B3
1Lovelace Respiratory Research Institute, Albuquerque, NM, USA, 2The University of North
Carolina at Charlotte, Charlotte, NC, USA, 3AstraZeneca, Wilmington, DE, USA
OBJECTIVES: Previous research has shown that high utilization of short-acting B-
agonists (SABA) is associated with asthma exacerbations, however annual assessments 
present signiﬁ cant barriers to real-time assessment needed for effective intervention. 
We explored a quarterly assessment of high SABA utilization patterns on subsequent
asthma exacerbations. METHODS: A retrospective cohort study conducted using
PHARMetrics database included health plan members (aged 6–56 years; n  93,604) 
with asthma and two-year continuous enrollment between 7/2003–6/2007, 1 hospi-
talization/emergency department (ED) or 2 outpatient claims of International Classi-
ﬁ cation of Diseases, 9th Revision, Clinical Modiﬁ cation (ICD-9-CM) code 493.XX
and 1 asthma medication claim in each of the two years of observation. Patients with 
COPD and diseases associated with chronic oral steroid use were excluded. SABA 
utilization was converted to canister-count in their ﬁ rst observed quarter and catego-
rized into 0, ½-1, 1½-2, 2. Risk of an asthma exacerbation in the subsequent quarter,
deﬁ ned as an oral steroid claim, hospitalization, or ED visit, was assessed using logistic
regression, controlling for age, sex, region, and several ﬁ rst-quarter severity measures/
comorbidities. RESULTS: The cohort included 33,951 patients aged 6–17 (36%) and 
59653 aged 18–56 (64%) of which 64% had 0 SABA canisters, 18% had ½-1, 9% 
had 1½-2, and 9% had 2. Compared to 0 canisters, higher SABA utilization was 
associated with higher exacerbation risk [½-1 (OR:1.01; CI:0.92–1.12), 1½-2 
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(OR:1.16; CI:1.03–1.31), and 2 (OR:1.47; CI:1.30–1.65)]. Findings were similar
when stratifying the sample by age group. CONCLUSIONS: Findings suggest that a 
quarterly assessment of SABA utilization can be used to identify patients at risk for
asthma-related exacerbations. The incidence of an asthma exacerbation was associated
with greater SABA use in the previous quarter.
RR2
HEALTH CARE UTILIZATION AND COST OF COPD IN A MEDICAID
POPULATION: THE ROLE OF CO–MORBID CONDITIONS
Lin PJ, Shaya FT
University of Maryland, Baltimore, MD, USA
OBJECTIVES: Comorbidities in patients with chronic obstructive pulmonary disease
(COPD) are associated with higher mortality, hospitalization, and poor quality of life. 
The objectives of this study were to characterize a comprehensive comorbidity proﬁ le 
among COPD patients, and to explore the impact of comorbidities on medical utiliza-
tion and cost in a low-income Medicaid population. METHODS: This retrospective 
cohort study analyzed medical claims from the Maryland Medicaid database. We
employed a 1:2 case-control design to select 1388 COPD patients aged 40 to 64 years 
with at least 24 months of continuous enrollment and 2776 demographically-matched
controls without COPD. Logistic regressions were performed to calculate odds ratios
that compared differences in the prevalence of comorbidities, including 17 conditions
deﬁ ned by the Charlson Comorbidity Index (CCI) and 6 additional conditions known 
to coexist with COPD. Generalized linear models were performed to estimate the
average medical utilization and cost by speciﬁ c comorbidity. RESULTS: Medicaid 
COPD patients had more comorbidities compared with non-COPD controls (CCI 
score  1.56 vs. 1.37, p  0.004), and were more likely to have myocardial infarction,
congestive heart failure, cerebrovascular disease, peptic ulcer, mild liver disease, hyper-
tension, sleep apnea, tobacco use, and edema. COPD patients on average had 16 more 
medical claims (81.4 vs. 65.4, p  0.001) and incurred $1871 higher medical cost per
year than non-COPD controls ($7603 vs. $5732, p  0.001). Ten out of the 17 condi-
tions deﬁ ned by the CCI as well as hypertension, tobacco use, and edema were associ-
ated with the excess medical utilization and cost in COPD patients. Depression was
associated with excess medical utilization but not cost. CONCLUSIONS: Medicaid
COPD patients have a substantial burden of comorbidities, which translate into higher
medical utilization and cost. Effective disease management and treatment protocols
are needed to reduce co-morbidity burden.
RR3
USE OF HEALTH CARE SERVICES IN PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATED WITH 
BUDESONIDE/FORMOTEROL VIA DRY POWDER INHALER
(BUD/FM DPI) VERSUS TIOTROPIUM DPI
Blais L1, Forget A2, Ramachandran S3
1Université de Montréal, Montreal, QC, Canada, 2Hôpital du Sacré-Coeur de Montréal, 
Montréal, QC, Canada, 3AstraZeneca LP, Wilmington, DE, USA
OBJECTIVES: To assess real-world effectiveness of BUD/FM DPI versus tiotropium
DPI in COPD patients METHODS: Data from the Quebec health care databases
were used to construct a matched cohort of COPD patients aged d40 years newly
treated with BUD/FM DPI or tiotropium DPI from 2003–2007. Patients were matched 
on age, sex, COPD exacerbations (short-course prescription of oral corticosteroids
[OCSs], emergency department [ED] visits or hospitalizations for COPD; d2 events
occurring within 15 days counted as 1 exacerbation), and use of short-acting
inhaled a]2-agonists (SABAs) and ipratropium in the year before therapy began. 
The number of exacerbations, ED visits, and hospitalizations for COPD; claims
for OCS prescriptions; and the average weekly doses (dose  2 inhalations) of 
SABAs and ipratropium were compared for BUD/FM DPI versus tiotropium DPI 
users for a 1-year post-therapy period. Poisson and linear regression models were used
to produce adjusted rate ratios (RR) and mean differences (MD). RESULTS: Of 
981 BUD/FM DPI and 981 tiotropium DPI users in the cohort, 78% were aged „d 
65 years and 53% were men. No signiﬁ cant differences were seen for COPD exacerba-
tions (RR  0.94; 95% CI, 0.77–1.15), ED visits for COPD (RR  0.80; 95% CI,
0.54–1.20), and claims for OCS prescriptions (RR  0.93; 95% CI, 0.72–1.21) 
between BUD/FM DPI and tiotropium DPI users in the year after the start of 
therapy. However, BUD/FM DPI users had signiﬁ cantly fewer hospitalizations for
COPD (RR  0.65; 95% CI, 0.44–0.97), used less SABAs (MD  0.48; 95% CI,
0.67 to 0.28), and used more ipratropium (MD  0.35; 95% CI, 0.21–0.50).
CONCLUSIONS: These ﬁ ndings showed that patients using BUD/FM DPI were sig-
niﬁ cantly less likely to have COPD exacerbations leading to a hospitalization, but as 
likely as tiotropium DPI users to require emergency care or OCS therapy in the year 
after initiation of therapy.
RR4
OUTCOMES ASSOCIATED WITH TIOTROPIUM USE IN COPD PATIENTS
Lee TA1, Wilke CT2, Joo M3, Stroupe KT4, Krishnan JA5, Schumock GT2, Pickard AS2
1Hines VA Hospital and Northwestern University, Chicago, IL, USA, 2College of Pharmacy, 
University of Illinois at Chicago, Chicago, IL, USA, 3Hines VA Hospital and University of Illinois 
at Chicago, Chicago, IL, USA, 4Midwest Center for Health Services & Policy Research, Hines, 
IL, USA, 5University of Chicago, Chicago, IL, USA
OBJECTIVES: To date, there is mixed evidence on the safety and effectiveness of 
tiotropium. Our objective was to evaluate the comparative effectiveness of regimens
containing tiotropium versus other medication regimens for chronic obstructive pul-
monary disease (COPD) in real-world clinical settings. METHODS: We conducted a 
cohort study on two separate cohorts with a diagnosis of COPD in the VA health care 
system. Patients with a COPD diagnosis prescribed tiotropium and patients in a his-
toric cohort prior to the introduction of tiotropium were selected for comparison using
propensity scores, with the base case including scores from 0.1 to 0.4. Outcomes
identiﬁ ed during follow-up were all-cause mortality, COPD exacerbations, and
COPD hospitalizations. Exposure to COPD medication regimens was deﬁ ned in a
time-varying manner and Cox proportional hazards regression were employed to
evaluate outcomes. RESULTS: For 42,090 patients in the base case, the regimen of 
tiotropium plus inhaled corticosteroids plus long-acting beta-agonists was associated 
with 40% reduced risk of death (HR  0.60 [95% CI 0.45, 0.79]) compared to inhaled
corticosteroids plus long-acting beta-agonists. This combination was also associated 
with reduced rates of COPD exacerbations (HR  0.84 [0.73, 0.97]) and COPD hos-
pitalizations (HR  0.78 [0.62, 0.98]). Tiotropium in combination with other medica-
tion regimens was associated with increased risk of events compared to inhaled 
corticosteroids plus long-acting beta-agonists. CONCLUSIONS: When used with 
inhaled corticosteroids and long-acting beta-agonists, tiotropium use was associated 
with a decreased risk of mortality compared to treatment with inhaled corticosteroids
and long-acting beta-agonists. However, this result was not consistent in other medica-
tion regimens that included tiotropium.
POSTER SESSION I
CONCEPTUAL PAPERS & RESEARCH ON METHODS – 
Clinical Outcomes Methods
PMC1
CLASSIFYING PATIENTS WITH METABOLIC SYNDROME USING THE
LATENT CLASS ANALYSIS (LCA)
Liu G1, Luo N2, McCollam PL3
1Peking University, Beijing, China, 2National University of Singapore, Singapore, Singapore, 3Eli
Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To identify subgroups of metabolic syndrome patients who would
be more homogeneous in terms of metabolic risk factors. METHODS: The 
electronic medical record database from GE Healthcare was used for this study. The 
database comprises de-identiﬁ ed longitudinal medical records of nationally repre-
sentative patients attending general practitioners. All adult patients were assessed 
for the presence of metabolic syndrome using the guidelines proposed by the 
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). 
A latent class analysis was conducted based on the abnormality of patients’ metabolic 
risk factors including triglycerides (TG; q150 mg/dL), high-density lipoprotein 
cholesterol (HDL-C; men: 40 mg/dL; women: 50 mg/dL), blood pressure (BP; sys-
tolic q130 mmHg, diastolic q85 mmHg, or drug treatment for hypertension), fasting
plasma glucose (q100 mg/dL or drug treatment for diabetes mellitus), and waist cir-
cumference (WC; men: q102 cm; women: q88 cm). The ﬁ nal model was selected based 
on model ﬁ t indices including Akaike’s information criterion, Bayesian information 
criterion (BIC), and sample-size adjusted BIC. RESULTS: Metabolic syndrome was 
present in 19,251 individuals. The prevalence of high blood pressure was 96.4%. All 
the ﬁ t indices in the LCA modeling pointed to a 5-class solution. In addition to high 
blood pressure, members of Class 1 (6.5%) had abnormal TG and HDL-C; members 
of Class 2 (4.6%) had abnormal HDL-C and WC; members of Class 3 (19.7%) had 
abnormal TG and WC and the majority also had abnormal HDL-C (probability: 
68.7%); members of Class 4 (8.2%) had abnormal plasma glucose and WC; and
members of Class 5 (61.1%) had high probability of abnormality in all metabolic risk 
factors (range: 79.9–100%). CONCLUSIONS: LCA represents a new method for 
casemix study of patients with metabolic syndrome. The subgroups of metabolic syn-
drome identiﬁ ed in this study need to be further studied for its usefulness in clinical
and health services research.
PMC2
LONGITUDINAL DATA EXPLORATION WITH STACKED CUMULATIVE
PERCENT PLOTS FOR CATEGORICAL DATA
Gilligan TM, Hill CD
RTI Health Solutions, Research Triangle Park, NC, USA
Longitudinal clinical trial data present analysts with the unique challenge of summariz-
ing large trends over time without losing the detail of changes from one timepoint 
to the next. Analysts must ﬁ nd a balance between the preservation of details at
each timepoint and parsimonious output that can be easily summarized and inter-
preted. For instruments that measure outcomes using nominal or ordinal response 
categories, analysts may want to preserve categorical information by reporting
response category frequencies over time. In this case, the frequency of change across
the course of treatment or disease progression is more informative, and perhaps more
appropriate, than mean or median change. Collapsing responses into mean or medians 
draws attention to overall trends, while losing the ability to detect movement from
one category response to another. A novel data visualization solution, stacked cumula-
tive percent plots, allows analysts to retain individual categorical responses and 
track the movement of categorical responses over time. Comparisons of stacked 
cumulative percent plots with mean plots illustrate the additional information that 
can be learned from retaining categorical information. Further, a variation of the 
proposed plot allows analysts to visualize the frequency of response category changes 
